Supira Medical

Executive Summary

Supira Medical is a clinical-stage medical device company developing a next-generation percutaneous ventricular assist device (pVAD) designed for temporary mechanical circulatory support. The device aims to deliver high continuous flow with a low-profile system, addressing the critical needs of patients undergoing high-risk percutaneous coronary intervention (PCI) or experiencing cardiogenic shock. Founded in 2018 as a Shifamed portfolio company, Supira operates out of Santa Clara, California. Its technology promises to improve hemodynamic stability with a smaller vascular footprint compared to existing pVADs, potentially reducing complications and enabling broader use in interventional cardiology. The cardiovascular medical device market is large and growing, with pVADs playing an increasingly vital role in treating complex coronary disease and acute heart failure. Supira differentiates itself through its proprietary pump design that balances high flow performance with a low-profile delivery system. The company is currently advancing its device through clinical studies, with key milestones expected in the coming quarters. If successful, Supira could capture significant market share in the temporary circulatory support space, currently dominated by devices like Impella. The company's strong backing from Shifamed and proximity to Silicon Valley innovation resources position it well for future growth and potential strategic partnerships.

Upcoming Catalysts (preview)

• Q4 2026Completion of Early Feasibility Study for High-Risk PCI80% success
• Q2 2026FDA Breakthrough Device Designation60% success
• Q3 2026Series C Funding Round70% success